MedPath

A Prospective Researcher-led Clinical Study of Neopep-S-based EasyDew MD Regen Cream

Not Applicable
Completed
Conditions
Skin Lesion
Interventions
Device: EasyDew MD regen cram
Registration Number
NCT05994781
Lead Sponsor
Eun-ji Kim
Brief Summary

This clinical study is conducted prospectively for 3 months after medical device treatment.

It is a comparative clinical study of the leading control group.

Detailed Description

Subjects need tissue transplantation to repair skin defects, so partial layer skin transplantation is performed. After proceeding, the patient is no longer subject to exudation. Subjects (and/or legal representatives) have agreed in writing to participate in the clinical study Perform a post-screening test.

Evaluating the screening test results, meeting the selection criteria, and meeting the exclusion criteria those who do not are registered for clinical research.

In the case of the study group among the subjects of the clinical study, whether partial layer skin transplantation was performed or not, Apply an appropriate amount of EasyDew MD Regen Cream twice a day (morning and evening) and can be absorbed well.

The control group is a non-treatment group, and for 3 months after the procedure. General moisturizers that have been used or will be used are available. The control group's Moisturizer is recommended twice a day (morning and evening) on whether skin grafts are collected or not Apply and allow good absorption. After applying medical devices and moisturizers for clinical research, the progress will be observed for 3 months, Subjects are a screening visit (Visit1), the day of medical device application (Visit2), and after medical device application.

Visit the research institution regularly for one month (Visit3) and three months after application (Visit4) for validity and it will be evaluated for safety.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • adults over the age of 19
  • Subjects with partial layer skin transplantation
  • There is no evidence of infection in the skin transplant process, and exudate is no longer present a person who does not arise
  • Decide to participate in this clinical study arbitrarily and in the written informed consent a person
Exclusion Criteria
  • showing signs of infection requiring antibiotic administration throughout the body or skin transplantation Case
  • In situations where the requirements of a clinical study cannot be complied with
  • When the researcher's judgment determines that the participation of the study is inappropriate (e.g. Kelloid personality)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TreatmentEasyDew MD regen cramIn the case of the study group among the subjects of the clinical study, The experimental group apply an appropriate amount of EasyDew MD Regen Cream twice a day (morning and evening) and can be absorbed well.
Primary Outcome Measures
NameTimeMethod
TEWL scoreBefore, after one month after application, 3 month after application

Transepidermal water loss score/ No range of upper and lower score, the lower is best

Secondary Outcome Measures
NameTimeMethod
Investigator Global Assessment scaleBefore, after one month after application, 3 month after application

Assess the patient's overall condition /lowest 0 score ( best score) to highest 30 score( worst score)

itching scaleBefore, after one month after application, 3 month after application

Evaluate the Itching scale / lowest 1 score ( best score) to highest 5 score( worst score)

Dermatology Life Quality IndexBefore, after one month after application, 3 month after application

Assess patient quality of life / lowest 0 score ( best score) to highest 4 score( worst score)

VSSBefore, after one month after application, 3 month after application

Vancouver Scar Scale/ No range of upper and lower score, the lower is best

Trial Locations

Locations (1)

Ajou University Hospital

🇰🇷

Gyeonggi-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath